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DObjective: Despite continued technical improvements, results of transcatheter radiofrequency ablation of atrial
fibrillation may be suboptimal in some patient subgroups. Short-term follow-up of minimally invasive epicardial
ablation of isolated atrial fibrillation has been encouraging.
Methods: One hundred four patients with drug-refractory isolated atrial fibrillation underwent minimally inva-
sive surgical ablation through right 3- to 4-cm minithoracotomy by isolation of pulmonary veins and were
followed-up for an average of 17 months. Previous failed transcatheter ablation was not a criterion for this pro-
cedure. Antiarrhythmic drugs were continued until postoperative month 6, despite demonstration of stable sinus
rhythm.
Results: The procedure was confirmed to be safe (1 case of procedure-related morbidity, no operative deaths)
and effective (89% overall freedom from recurrent arrhythmia at follow-up, 96% freedom from paroxysmal
atrial fibrillation, 80% freedom from persisting type atrial fibrillation). Results tended to improve with the ex-
pansion of the surgical experience. Cox hazard regression and Kaplan-Meier analysis identified persisting type
atrial fibrillation and enlarged left atrium as the major predictors of recurrent atrial fibrillation at follow-up.
Health-related quality of life was confirmed to be improved at the end of the follow-up relative to baseline in
most Medical Outcomes Study 36-Item Short-Form Health Survey domains.
Conclusions: Minimally invasive epicardial ablation of isolated atrial fibrillation yields stable, gradually im-
proving results. Earlier surgical referral is justifiable after careful cardiologic work-up. To define the relative
roles of minimally invasive ablation and transcatheter ablation, which may be considered in the future as alter-
native therapies, a randomized trial to compare these procedures is advisable. (J Thorac Cardiovasc Surg
2011;142:e41-6)Atrial fibrillation (AF) is among the most common rhythm
disturbances in adults. This arrhythmia can lead to impor-
tant cardiovascular morbidity and mortality, mainly from
thromboembolism.1 Reduction in health-related quality of
life and increases in social expenditures also ensue, even
for patients with isolated AF. The rate of failure of medical
rhythm control therapy may be as high as 85% at 2 years.2
Transcatheter radiofrequency ablation has been recognized
as an effective second-line treatment to obtain rhythm con-
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The Journal of Thoracic and Catechnologies, the recurrence rate of AF may be still consid-
erable (about 30% at 30 months).4
Currently, the surgical epicardial ablation of isolated,
drug-refractory AF is possible through minimally invasive
access and with the heart beating. The safety of this tech-
nique and encouraging short-term results were reported
from our initial experience, including a 13% rate of recur-
rence at 6 months.5 AF is an insidious disease, however, and
may recur over time. Therefore longer follow-up periods
and a greater number of patients are required to address ad-
equately the reliability of any ablation technique. This arti-
cle outlines the results of the minimally invasive ablation of
isolated AF at midterm follow-up and discusses the poten-
tial implications for the current treatment algorithms for
isolated AF.MATERIALS AND METHODS
Patient Selection
The program of epicardial minimally invasive ablation of isolated AF
was started at our institution in June 2008. A total of 104 patients under-
went this treatment and were enrolled in this investigation. Patients were
scheduled for surgery on the basis of the following criteria: (1) recurrentrdiovascular Surgery c Volume 142, Number 2 e41
Abbreviations and Acronyms
AF ¼ atrial fibrillation
SR ¼ sinus rhythm
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tolerated doses of class IC or III antiarrhythmic agents, alone or in combi-
nation, and (2) at least 1 failed electrical or pharmacologic cardioversion
attempt during the 6 months preceding the surgical evaluation. At preoper-
ative echocardiography, the left atrial diameter was assessed in the para-
sternal long-axis view and indexed to the body surface area. In the
second half of our experience, significantly but not excessively increased
left atrial dimension was not considered an exclusion criterion for the pro-
cedure; however, left atrial dimension indexed to body surface area exceed-
ing 35 mm/m2 was considered an exclusion criterion for the procedure in
the entire study population. All enrolled patients with indexed left atrial
sizes between 22 and 35 mm/m2 were considered to have an enlarged
left atrium. AF was considered paroxysmal when self-terminating and last-
ing less than 7 days. Persisting AF was diagnosed when AF lasted more
than 7 days but less than 6 months or when it had to be terminated by
direct-current or pharmacologic cardioversion.Surgical Technique
Oral anticoagulation therapy was withdrawn 3 days before the proce-
dure, and the patients were put on a regimen of enoxaparin sodium at
4000 IU twice daily until the evening before surgery. The preoperative anti-
coagulation regimen was resumed on the day after surgery. The operative
technique has been already described in a previous publication.5 Briefly,
with the patient under general anesthesia, a 3- or 4-cm right minithoracot-
omy was performed at the 3rd intercostal space, and a soft-tissue retractor
was applied. Transesophageal echocardiography was performed before
commencement of the procedure to rule out intra-atrial thrombus. To en-
sure lack of thrombus, we submitted patients to isolated AF surgery after
a conventional period of at least 3 weeks of oral anticoagulant therapy.6
It was generally feasible to reach the pericardium while keeping both lungs
inflated by means of a gentle traction to the middle lobe of the right lung.
Collapse of the right lung could be achieved whenever required to amelio-
rate the exposure. Under direct vision but with the help of thoracoscopic
camera, the pericardium was incised parallel to the right phrenic nerve
and the oblique sinus was entered by blunt dissection. The COBRAAdhere
XL System (Estech, San Ramon, Calif) was used in all cases. This device is
designed to obtain electrical isolation of the pulmonary veins by radiofre-
quency ablation of the atrial myocardium in an entirely off-pump proce-
dure. An introducer equipped with a magnetic tip was pushed into the
transverse sinus until the left atrial appendage was passed. A second intro-
ducer was pushed into the oblique sinus until its tip joined the first intro-
ducer. A loop was then formed, and at this stage care was taken to avoid
inadvertent lesion of the left atrial appendage. The ablation probe was
guided into position, and its branches were tightened so that the 4 pulmo-
nary veins were encircled. The device used suction to stabilize the contact
with the myocardium and achieve uniform energy delivery. A circular box
lesion was created with radiofrequency energy. Different patterns of energy
delivery are available with the device used; in our experience, ablation was
performed more commonly by 2 energy applications lasting 150 seconds
each. These were followed by a 60-second application after the probe
was moved circumferentially, to achieve complete closure of the box le-
sion. After the probe was withdrawn, efficacy assessment was usually
done by measurement of conduction across the lesion. Conduction block
was evaluated with pacing from the pulmonary veins (exit block). Com-
plete block was considered to be indicative of effective electrical isolation.
The operative field was inspected, and the chest was closed.e42 The Journal of Thoracic and Cardiovascular SurgFollow-up
The patients were transferred to the intensive care unit, where electrical
cardioversion could be performed in the early postoperative period when-
ever needed. The patients were scheduled for regular follow-up visits at 3
and 6 months after discharge from the hospital and every 6 months
thereafter. Visits consisted of physical examination, New York Heart Asso-
ciation functional classification, surface electrocardiogram, 24-hour elec-
trocardiographic monitoring, and transthoracic echocardiography. The
echocardiographic examination included pulsed Doppler analysis of the
transmitral flow (the presence of a filling Awave with a peak flow velocity
of 0.4 m/s or more was considered indicative of adequate atrial transport
function). Telephone interviews were also performed on a monthly basis
to enquire as to each patient’s status. Patients were also instructed to con-
tact our center in the event of any symptoms. After such contact, a patient
was admitted for an unscheduled visit, including 24-hour electrocardio-
graphic tracings. Health-related quality of life was assessed before surgery
and at any follow-up visit by administration of the Medical Outcomes
Study 36-Item Short-Form Health Survey.7 This questionnaire provides
a score for each of the following domains: physical activity, role limitation,
physical pain, general health, vitality, social activity, and mental health.
According to our protocol, all patients were discharged on a regimen of
both oral amiodarone (or flecainide acetate) and warfarin sodium despite
demonstration of stable sinus rhythm (SR). Dismal clinical results and un-
acceptably high rates of AF recurrence may follow if antiarrhythmic med-
ications are withheld immediately after successful ablation.8 After
demonstration of stable SR at both the 3- and 6-month visits, amiodarone
(or other antiarrhythmic drug) was withdrawn. For all patients who had the
antiarrhythmic drugs suspended, additional 24-hour electrocardiographic
monitoring was scheduled at 1 and 3 months after drug withdrawal. When-
ever stable SR was found to be maintained 3 months later on, oral antico-
agulation was withdrawn as well. For the purposes of this study,
thromboembolic events were defined as radiologic demonstration of
a new ischemic area within the brain (ischemic stroke) associated with
a new focal neurologic deficit or coma.
Study End Points
Study end points were as follows:
1. One-year clinical results of rate of recurrence of AF, freedom from an-
tiarrhythmic medications, freedom from oral anticoagulant drugs, free-
dom from thromboembolic events, and health-related quality-of-life.
2. Left atrial transport function at 1-year follow-up (pulsed Doppler
examination).
3. Factors associated with AF recurrence during follow-up.
Data Management and Statistical Analysis
Individual patients’ data were prospectively collected with preformatted
data sheets and included in an electronic database, which was periodically
checked for errors and omissions. Data were processed with SPSS software
version 13.0 (SPSS Inc, an IBM Company, Chicago, Ill). Continuous vari-
ables are presented as mean  SD, and categorical variables are presented
as percentages. Intergroup comparisons were performed with the 2-tailed
Student t test (continuous variables) or the c2 test (categorical variables)
for unpaired data. Time-to-event analysis (Cox proportional hazards re-
gression) was used to identify the predictors of AF recurrence during the
follow-up. The assumptions of Cox regression were checked and met,
and the model was successfully tested. The variables entered in the model
as potential explanatory variables were the following: age, sex, type of AF
(persisting or paroxysmal), left atrial dimension, previous electrical cardi-
oversion or transcatheter ablation, pattern of radiofrequency ablation appli-
cations delivered, preoperative New York Heart Association functional
status, left ventricular ejection fraction, diabetesmellitus, arterial hyperten-
sion, and class of antiarrhythmic drugs used. For the purposes of Cox haz-
ards regression, the left atrial diameter was entered as a continuousery c August 2011
TABLE 2. Follow-up results in the overall study population (n ¼ 104)
Intensive care unit stay (h, mean  SD) 18.1  4.7
Operative morbidity (any, no.) 3 (2.9%)
Recurrent atrial fibrillation (no.) 11 (10.6%)
Freedom from antiarrhythmic drugs (no.) 53 (51%)
Freedom from oral anticoagulant therapy (no.) 41 (39.4%)
Thromboembolic events (no.) 1 (0.9%)
No evidence of atrial transport function* (no.) 12 (11.5%)
*Impossible to demonstrate filling Awave with peak flow velocity of 0.4 m/s or more
at pulsed transmitral Doppler.
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curves, the left atrial dimension was managed as a dichotomous variable.
In such instance, an indexed left atrial size of at least 22 mm/m2 was con-
sidered indicative of an enlarged left atrium. Recurrent AF–free survival
was analyzed according to the Kaplan-Meier method, and corresponding
survival curves were built. Comparisons of survival estimates for different
patient strata were performed with the log-rank statistic.
RESULTS
Operative Results
The baseline characteristics of the overall study popula-
tion are reported in Table 1. A total of 104 patients were in-
cluded in this investigation. Intraoperative transesophageal
echocardiography could not demonstrate the presence of
intra-atrial thrombus in any patient. Mean operative time
was 82  33 minutes. In the overall population, we had
no operative deaths and 3 cases of periprocedural complica-
tions. Intraoperative rupture of the left atrial appendage oc-
curred in 1 case during the earliest phase of our surgical
experience; emergency sternotomy was required for repair.
In 1 patient, hemorrhagic stroke with hemiplegia occurred 4
days after surgery; this patient was receiving long-term an-
ticoagulant therapy and had 2 previous episodes of intracra-
nial hemorrhage before being submitted to arrhythmia
surgery. We therefore considered this morbidity episode
not to be procedure related. The third patient had a transient
ischemic attack in the early postoperative period; no throm-
bus had been localized within the left atrium or left append-
age. Both patients were in SR at the time of morbidity.
Twenty patients (19.5%) were subjected to electrical cardi-
oversion before hospital discharge as a result of persisting
AF or supraventricular tachycardia. No further instances
of perioperative morbidity were recorded. All patients but
1 were discharged in SR and on a regimen of antiarrhythmic
drugs (amiodarone or flecainide).
Follow-up Results
The average follow-up was 17.1  5.8 months (range,
2–19 months). Follow-up was 100% complete. The results
obtained in the overall study cohort are summarized in
Table 2. During the follow-up, 2 patients died of non–
cardiac related causes (trauma in 1 case and malignant neo-TABLE 1. Baseline characteristics of the overall study population
(n ¼ 104)
Age (y, mean  SD) 63.9  8
Sex (male/female ratio) 39:65
Left atrial dimension (mm/m2, mean  SD) 21.3  3
Diabetes mellitus (no.) 21 (20.2%)
Hypertension (no.) 54 (51.9%)
Previous electrical cardioversion (no.) 36 (34.6%)
Previous transcatheter ablation (no.) 24 (23.1%)
Class I antiarrhythmic drugs (no.) 39 (37.5%)
Class II antiarrhythmic drugs (no.) 8 (7.7%)
Class III antiarrhythmic drugs (no.) 68 (65.4%)
The Journal of Thoracic and Caplasm in the second case). One thromboembolic event was
recorded. At the end of the follow-up, we recorded a total of
11 clinical relapses of AF (89.4% overall freedom from
AF). Two of the 11 relapses occurred in patients who had
a preoperative diagnosis of paroxysmal AF (P ¼ .02 vs pa-
tients with a diagnosis of persisting AF). Cardioversion was
performed during the follow-up in 6 of these patients. Thus
the freedoms from recurrent AF at the end of the follow-up
were 96% among patients with a preoperative diagnosis of
paroxysmal AF and 80% among patients with a preopera-
tive diagnosis of persisting AF. According to the previously
described protocol, 41 patients who were in stable SR after
the 9th postoperative month had both the antiarrhythmic
and the anticoagulant medications withdrawn (freedom
from any drug 39.4%). An additional 12 patients (11.5%)
stopped taking antiarrhythmic drugs after the 6th postoper-
ative month. All patients who had the antiarrhythmic drugs
withdrawn remained in stable SR during all the available
follow-up after drug withdrawal (average time 4.1  0.9
months). Among the 41 patients whowere no longer receiv-
ing antiarrhythmic drugs, 8 (19%) independently sus-
pended their pharmacologic therapy at an average of 4.5
postoperative months. As stated previously, none of these
patients had recurrent atrial arrhythmia during the available
follow-up. Conversely, 5 of the 11 patients who had recur-
rent AF (45%) independently gave up their antiarrhythmic
drugs before reaching the scheduled follow-up reassess-
ment. Pulsed Doppler examination performed at the latest
follow-up visit available indicated that 92 of 93 patients
in SR (98.9%) had signs of atrial function. A-wave velocity
in these patients ranged from 0.4 m/s to 0.76 m/s (average
0.51  0.2 m/s). The single patient without atrial transport
function despite lack of electrocardiographic evidence of
AF had a preoperative history of the persisting type of AF
and an enlarged left atrium.
Table 3 reports the results of Cox proportional hazards re-
gression. Significant predictors of AF recurrence during theTABLE 3. Results of Cox proportional hazards regression: Predictors
of recurrence and time to recurrence of atrial fibrillation
Characteristic Wald Risk ratio P value
Persisting atrial fibrillation 5.3 1.36 .004
Left atrial dimension 11.8 3.7 <.001
rdiovascular Surgery c Volume 142, Number 2 e43
FIGURE 1. Kaplan-Meier survival curves. A, Recurrent atrial fibrillation–free survival in the overall study population. B, Recurrent atrial fibrillation–free
survival in patients with preoperative diagnosis of paroxysmal atrial fibrillation (upper line) versus persisting atrial fibrillation (lower line log-rank P¼ .02).
C, Recurrent atrial fibrillation–free survival in patients with preoperative demonstration of enlarged left atrium (LA, lower line) versus patients without sig-
nificantly increased left atrial dimension (upper line, log-rank P<.001). Cum, Cumulative.
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atrial dimension. Kaplan-Meier analysis indicated that both
the persisting type of AF and enlarged left atrium were sig-
nificantly associated with a worse AF-free survival
(Figure 1). These findings confirm previous data and have
potential implications regarding the selection of patients
to be submitted to surgery for isolated AF.
In Table 4, we have compared the baseline characteristics
and clinical results of the patients operated on during the
initial part of our surgical experience (as previously re-
ported5) with those of the patients who were operated on
subsequently. There was no statistically significant differ-
ence in terms of AF relapse rate between patients who
had an average 6 months of follow-up and those who had
a longer average follow-up (8.6% vs 13%, respectively).
A trend toward a lower rate of recurrent AF was observed
in the latter group, although the difference did not reach sta-TABLE 4. Comparison of baseline characteristics, operative
characteristics, and follow-up results of patients who underwent
minimally invasive ablation of isolated atrial fibrillation in the first
experience period (n¼ 46) versus the second experience period (n¼ 58)
Characteristic First Second P value
Left atrial dimension (mm/m2,
mean  SD)
21.2  3 21.4  3 .58
Age (y, mean  SD) 63.4  9 64.1  9 .82
Diabetes mellitus (no.) 10 (21.7%) 11 (19%) .7
Hypertension (no.) 26 (56.5%) 28 (48.3%) .45
Previous failed
electrocardioversion (no.)
14 (30.4%) 19 (32.7%) .9
Intensive care unit stay
(h, mean  SD)
18.7  5.1 17.7  5 .71
Operative morbidity (any, no.) 2 (1.9%) 1 .8
Recurrent atrial fibrillation at
follow-up (no.)
6 (13.04%) 5 (8.6%) .12
e44 The Journal of Thoracic and Cardiovascular Surgtistical significance. This observation, nevertheless, may be
clinically significant. Such a concept is strengthened by the
comparability of these groups in terms of the baseline fac-
tors associated with the AF burden (left atrial dimension,
age, diabetes mellitus, hypertension, and left ventricular
ejection fraction).
We confirm previous findings that the average 36-Items
Short-Form Health Survey–related domains show a statisti-
cally significant improvement at the end of the follow-up
relative to the baseline value, except for the vitality indices.
Particularly, a remarkable amelioration was seen for the fol-
lowing parameters: physical activity (P<.001), role limita-
tion (P<.001), general health (P<.001), social activities
(P<.001), and mental health (P ¼ .02).DISCUSSION
A therapeutic gap still exists for patients with isolated
AF. Despite ongoing research and continued improvements
in the treatment protocols and transcatheter radiofrequency
ablation technology, the rate of recurrence of AF after
second-line treatment (transcatheter ablation) in patients
with drug-refractory AF may reach 30%.4 Many patients
therefore remain exposed to thromboembolic events and
need anticoagulation indefinitely. This study was conceived
to evaluate the long-term clinical results of the radiofre-
quency surgical epicardial ablation of isolated AF through
minimally invasive access. A device designed for monolat-
eral right minithoracotomy approach and a completely off-
pump strategy were used.9 It has been already reported that
such device has a good safety and feasibility profile, and the
early results have been encouraging (87% freedom from re-
current AF at an average of 6 months).5 Here we report
a continued follow-up (17.1  5.8 months) and a larger se-
ries. The expanding experience led to a reduced rate of
procedure-related serious adverse events and to a gradualery c August 2011
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global rate of freedom from recurrent AF was 89.4% at
the end of the follow-up. This is reflected by the finding
that the benefits in terms of the quality-of-life indices are
consolidated with time.
In this series, we also analyzed the first cohort of patients
who had their antiarrhythmic and anticoagulant drug regi-
men withdrawn after achievement of stable SR during the
follow-up. About 51% of all patients were no longer receiv-
ing antiarrhythmic drugs at the end of the follow-up. All
these patients remained in stable SR after the withdrawal
of the antiarrhythmics (average follow-up available after
drug withdrawal, 4.1  0.9 months), which testifies to the
stability with time of the results of this procedure. Most
clinical recurrences of arrhythmia apparently occur within
a shorter period after surgery (average, 3.4 postoperative
months in our series). Interestingly, this resembles previous
evidence obtained for transcatheter ablation.4 Overall, im-
proved health-related quality of life and freedom from
any drugs represent the true therapeutic goal to be achieved
for these patients.
The operation described here holds the advantages of any
minimally invasive surgery: reduced morbidity, shortened
hospitalization, andminimized scar formation. The ablation
procedure is entirely off pump. This may consolidate the
clinical results in terms of early freedom from arrhythmia,
because postpump systemic inflammatory reaction is
a known independent trigger of AF.10 The ablation proce-
dure that we used is, however, confined to the left atrium.
Reduced exposure of the cardiac structures is the price we
pay to achieve minimal invasiveness and a fully off-pump
treatment. In a meta-analysis, it was reported that adding
a set of right atrial lesions to the isolation of the pulmonary
veins could confer superior results in terms of late arrhyth-
mia recurrence relative to the ablation patterns limited to the
left atrium.11 This meritorious work is limited, however, by
the inclusion of several retrospective trials published in the
1995 to 2005 period. More recently, randomized studies
have been conducted with novel ablation equipment and
have underlined that the clinical results (in terms of mainte-
nance of SR and freedom from thromboembolic events)
were comparable between the biatrial and left atrial proce-
dures.8,12,13 Such conclusions corroborate the practice of
the minimally invasive radiofrequency isolation of the
pulmonary veins, provided that adequate lesions can be
obtained (transmurality and lesion continuity are pivotal
requirements). Electrophysiologic data indicate that AF
generally has a biatrial pathophysiologic substrate in
patients with isolated arrhythmia.14 Nonetheless, our data
suggest that the electrical isolation of the pulmonary veins
is effective in reestablishing SR in most cases of isolated
AF. Electrophysiologic studies were not available in most
of our cases. The literature uniformly indicates that in-
creased left atrial dimension is the main predictor of AF re-The Journal of Thoracic and Cacurrence, and our results for patients with indexed left atrial
sizes between 22 and 35 mm/m2 (Cox regression and
Kaplan-Meier analysis) confirm this concept. Atrial dilata-
tion is considered a hallmark of established myocardial de-
rangements, even at the cellular level; such alterations are
not reversible and perpetuate the arrhythmia even in pa-
tients with isolated AF. At this stage, any ablative interven-
tion has lesser likelihood of success both in patients with
concomitant organic heart disease and in patients with iso-
lated AF. This is in agreement with the finding that less op-
timal results are obtained at follow-up in patients with
persisting rather than paroxysmal AF (Cox regression and
Kaplan-Meier analysis).15 Thus the degree of atrial de-
rangement should be probably considered the major patho-
physiologic marker of disease progression. The clinician
may establish decision making and surgical timing accord-
ing to such a marker. Ablation is most effective before ex-
cessive left atrial alterations have set in, and earlier
referral may therefore be recommended. We encourage
the development of larger investigations with comparison
of patients with paroxysmal versus persisting AF and com-
parisons of patients belonging to different strata according
to left atrial dimension. Consideration of minimally inva-
sive ablation for patients with an indexed left atrial size
greater than 35 mm/m2 should be evaluated. Ultimately,
such parameters (left atrial size class and AF type) should
be regarded as potential tools to refine the surgical timing.
A good concordance existed between electrocardio-
graphic documentation of stable SR at follow-up and dem-
onstration of atrial contraction. Nonetheless, our data
confirm that a 100% concordance may not be achieved.
The clinician thus should probably include echocardio-
graphic assessment of the atrial function in all patients fol-
lowed up after AF ablation, mainly if enlarged left atrium
and persisting type of AF coexist. Anticoagulant therapy
for prevention of ischemic stroke may be then considered.
Follow-up for arrhythmia recurrence was conducted with
24-hour electrocardiographic monitoring in this study. The
unavailability of data from 72-hour tracings and internal
loop recorder represents a limitation of this investigation.
Nonetheless, telephonic monitoring, patient education to
report any symptoms promptly, and liberal use of unsched-
uled visits and 24-hour electrocardiographic tracings are
likely to minimize arrhythmia underdetection during
follow-up.
In conclusion, this study supports the contention that the
results of minimally invasive ablation of drug-refractory
isolated AF by radiofrequency isolation of the pulmonary
veins are reliable with time (1-year average follow-up)
and that stable SR can be achieved with this technique in
most cases. The results tend to improve with the expansion
of the surgical experience. The rate of withdrawal of antiar-
rhythmic and anticoagulant drugs is encouraging, although
the precise requirement and duration of the postoperativerdiovascular Surgery c Volume 142, Number 2 e45
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less, it is remarkable that 45% of the patients undergoing
AF relapse independently suspended the antiarrhythmic
medications. This therapeutic option may be considered
for all patients with isolated, drug-refractory AF and previ-
ous failed cardioversion. The selection of candidates can be
enhanced, bearing in mind that increased left atrial size and
persisting type of AF is closely associated with late AF re-
currence. Earlier referral to surgery of patients with drug-
refractory isolated AF is therefore justifiable after a careful
cardiologic workup. The epicardial, minimally invasive,
off-pump ablation and the transcatheter ablation may be re-
garded in the future as alternative therapies; minimally in-
vasive surgery may be also considered as the first-line
treatment for selected patients with isolated AF. Neverthe-
less, a randomized trial should now be designed to compare
directly these 2 approaches, in view of the very good results,
safety, and consolidated experience with minimally inva-
sive epicardial surgery.
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